학술논문

Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry
Document Type
article
Author
Martine DumontNana Weber-LassalleCharles Joly-BeauparlantCorinna ErnstArnaud DroitBing-Jian FengStéphane DuboisAnnie-Claude Collin-DeschesnesPenny SoucyMaxime ValléeFrédéric FournierAudrey LemaçonMuriel A. AdankJamie AllenJanine AltmüllerNorbert ArnoldMargreet G. E. M. AusemsRiccardo BeruttiManjeet K. BollaShelley BullSara CarvalhoSten CornelissenMichael R. DufaultAlison M. DunningChristoph EngelAndrea GehrigWillemina R. R. Geurts-GieleChristian GiegerJessica GreenKarl HackmannMohamed HelmyJulia HentschelFrans B. L. HogervorstAntoinette HollestelleMaartje J. HooningJudit HorváthM. Arfan IkramSilke KaulfußRenske KeemanDa KuangCraig LuccariniWolfgang MaierJohn W. M. MartensDieter NiederacherPeter NürnbergClaus-Eric OttAnnette PetersPaul D. P. PharoahAlfredo RamirezJuliane RamserSteffi Riedel-HellerGunnar SchmidtMitul ShahMartin SchererAntje StäblerTim M. StromChristian SutterHolger ThieleChristi J. van AsperenLizet van der KolkRob B. van der LuijtAlexander E. VolkMichael WagnerQuinten WaisfiszQin WangShan Wang-GohrkeBernhard H. F. WeberGenome of the Netherlands ProjectGHS Study GroupPeter DevileeSean TavtigianGary D. BaderAlfons MeindlDavid E. GoldgarIrene L. AndrulisRita K. SchmutzlerDouglas F. EastonMarjanka K. SchmidtEric HahnenJacques Simard
Source
Cancers, Vol 14, Iss 14, p 3363 (2022)
Subject
breast cancer
genetic susceptibility
whole-exome sequencing
moderate-penetrance genes
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2072-6694
Abstract
Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.